Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. (Q38424919)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

review article

1 reference

title

Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

main subject

The Cancer Genome Atlas

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Seth P Lerner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

1 reference

6 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

Urologic Clinics of North America

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

201-15, viii

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

Molecular pathogenesis and diagnostics of bladder cancer

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Strategies for molecular expression profiling in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Genome-wide association study identifies multiple loci associated with bladder cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Mutational context and diverse clonal development in early and late bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Comprehensive molecular characterization of urothelial bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Mutational heterogeneity in cancer and the search for new cancer-associated genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Discovery and saturation analysis of cancer genes across 21 tumour types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Identifying distinct classes of bladder carcinoma using microarrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Three differentiation states risk-stratify bladder cancer into distinct subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Generation of a concise gene panel for outcome prediction in urinary bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Oncogenic FGFR3 gene fusions in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A molecular taxonomy for urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A precystectomy decision model to predict pathological upstaging and oncological outcomes in clinical stage T2 bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Nomograms provide improved accuracy for predicting survival after radical cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Molecular markers for bladder cancer: the road to a multimarker approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Bladder cancer outcome and subtype classification by gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A four-gene signature predicts disease progression in muscle invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A central role for long non-coding RNA in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Gene Expression Signatures Predict Outcome in Non-Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Predictors of cancer-specific mortality after disease recurrence following radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Factors influencing post-recurrence survival in bladder cancer following radical cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Trastuzumab containing regimens for early breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Expression profiling for bladder cancer: strategies to uncover prognostic factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Molecular targets and targeted therapies in bladder cancer management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase II study of sunitinib in patients with metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

mTOR signaling pathway and mTOR inhibitors in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase II study of everolimus in metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Genome sequencing identifies a basis for everolimus sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Accumulation of nuclear p53 and tumor progression in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Molecular biology of bladder cancer: prognostic and clinical implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

p53 and retinoblastoma pathways in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Molecular staging of bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Targeting heat shock proteins in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Heat shock protein 27 phosphorylation state is associated with cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Hsp27 silencing coordinately inhibits proliferation and promotes Fas-induced apoptosis by regulating the PEA-15 molecular switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Enhancement of antitumor immunity by CTLA-4 blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Theranostic and prognostic biomarkers: genomic applications in urological malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

p53 and treatment of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Searching for novel therapeutics and targets: insights from clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Emmprin and Survivin Predict Response and Survival following Cisplatin-Containing Chemotherapy in Patients with Advanced Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.01.003

10.1016/J.UCL.2015.01.003

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882562%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference